IMCR Q3 2024 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+23.7% YoY

Gross Profit

$80M99.4% margin

Operating Income

-$9M-10.6% margin

Net Income

$9M10.9% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$20M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$707M

Stockholders' Equity

$378M

Cash & Equivalents

$538M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$65M	+23.7%
Gross Profit	$80M	$65M	+23.6%
Operating Income	-$9M	-$14M	+39.9%
Net Income	$9M	$906,000	+864.2%

Geographic Segments

UNITED STATES

$57M71%

Europe

$21M26%

Rest of World

$2M2%